Access
To read this story in full you will need to login or make a payment (see right).
Books and Arts
Nature 453, 855-856 (12 June 2008) | doi:10.1038/453855a; Published online 11 June 2008
Open Innovation Challenges
-
Direct Molecular Detection of Proteins and Nucleic Acids
This Challenge is looking for novel approaches to protein and nucleic acid detection. This is an Id...
-
Single-cell Analysis Platform
This Challenge is looking for novel approaches to analyzing changes at a single-cell level. This is...
- More Challenges
- Powered by:
nature jobs
Gastroenterologist
- Gastrointestinal Diseases Inc.
- Georgia, USA
Head of Production Biopharmaceuticals
- Rhein Minapharm Biogenetics
- Cairo (Egypt)
A prescription for public health
Merrill Goozner1
Abstract
Will high drug prices and a lack of new medicines force the pharmaceutical industry to restructure and take a more personalized approach to research, asks Merrill Goozner.
BOOK REVIEWED-Reasonable Rx: Solving the Drug Price Crisis
by Stan Finkelstein & Peter Temin
FT Press: 2008. 208 pp. $27.99
Pharmaceutical executives will find nothing reasonable in the provocative view offered in Reasonable Rx. In this discussion of prescription drug (or Rx) policy, medical researcher Stan Finkelstein and economist Peter Temin of the Massachusetts Institute of Technology propose the break-up of pharmaceutical companies into two separate entities: one devoted to research and development (R&D) and the other to manufacturing and marketing.
To read this story in full you will need to login or make a payment (see right).
